Mountain Pacific Investment Advisers LLC Increases Stake in Eli Lilly and Company $LLY

Key Points

• Mountain Pacific Investment Advisers LLC increased its stake in Eli Lilly by 137.7% in the second quarter, now owning 844 shares valued at approximately $658,000.
• Eli Lilly reported a 37.6% year-over-year revenue increase, reaching $15.56 billion for the quarter, and exceeded earnings expectations by $0.72 with an EPS of $6.31.
• Insider trading activity includes CEO David A. Ricks purchasing 1,632 shares worth over $1 million, indicating continued confidence in the company's performance.

Mountain Pacific Investment Advisers LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 137.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 844 shares of the company's stock after buying an additional 489 shares during the period. Mountain Pacific Investment Advisers LLC's holdings in Eli Lilly and Company were worth $658,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC grew its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after buying an additional 40 shares during the last quarter. ST Germain D J Co. Inc. grew its holdings in Eli Lilly and Company by 3.4% during the 1st quarter. ST Germain D J Co. Inc. now owns 1,667 shares of the company's stock valued at $1,377,000 after buying an additional 55 shares in the last quarter. HBW Advisory Services LLC increased its stake in Eli Lilly and Company by 1.4% in the 1st quarter. HBW Advisory Services LLC now owns 1,648 shares of the company's stock worth $1,361,000 after acquiring an additional 23 shares during the last quarter. Finally, Triangle Securities Wealth Management raised its holdings in shares of Eli Lilly and Company by 30.3% during the 1st quarter. Triangle Securities Wealth Management now owns 4,814 shares of the company's stock worth $3,976,000 after acquiring an additional 1,120 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 8.2%

Shares of NYSE LLY opened at $825.92 on Thursday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market cap of $781.70 billion, a P/E ratio of 53.98, a PEG ratio of 1.06 and a beta of 0.47. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The firm has a 50-day simple moving average of $733.71 and a two-hundred day simple moving average of $766.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 earnings per share. The company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent research reports. Cantor Fitzgerald cut their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Finally, HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price target for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Insider Buying and Selling at Eli Lilly and Company

In related news, CEO David A. Ricks acquired 1,632 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jamere Jackson acquired 200 shares of the stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.